AR073010A1 - Compuesto amida con actividad agonista del gpr52 - Google Patents

Compuesto amida con actividad agonista del gpr52

Info

Publication number
AR073010A1
AR073010A1 ARP090103088A ARP090103088A AR073010A1 AR 073010 A1 AR073010 A1 AR 073010A1 AR P090103088 A ARP090103088 A AR P090103088A AR P090103088 A ARP090103088 A AR P090103088A AR 073010 A1 AR073010 A1 AR 073010A1
Authority
AR
Argentina
Prior art keywords
phenyl
substituents
dihydro
ring
group
Prior art date
Application number
ARP090103088A
Other languages
English (en)
Inventor
Yuhei Miyanohana
Masaki Setoh
Mitsunori Kouno
Masakuni Kori
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of AR073010A1 publication Critical patent/AR073010A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/10—Radicals substituted by halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/28—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

El compuesto puede ser provisto como agente terapéutico o de prevencion para la esquizofrenia o similar. Método y usos. Reivindicacion 1: Un compuesto caracterizado por la formula (1) donde A representa -CONRa- o -NRaCO-; Ra representa un átomo de hidrogeno o un sustituyente; B representa un átomo de hidrogeno o un sustituyente; o en forma alternativa, cuando A es -CONRa-, Ra y B pueden formar junto con un átomo de nitrogeno adyacente un grupo heterocíclico que contiene nitrogeno el cual puede tener uno o más sustituyentes; o además en forma alternativa, cuando A es -CONRa-, B puede unirse al átomo de carbono adyacente al átomo de carbono al cual -A-B está unido para formar un anillo de cinco o seis miembros el cual puede tener uno o más sustituyentes; el anillo Cy1 representa un anillo aromático de seis miembros el cual puede tener uno o más sustituyentes además de un grupo representado por -A-B; el anillo Cy2 representa un anillo de seis miembros el cual puede tener uno o más sustituyentes seleccionados de un átomo de halogeno, un grupo ciano, un grupo hidroxi, un grupo hidrocarburo-oxi el cual puede tener uno o más sustituyentes, un grupo hidrocarburo en cadena el cual puede tener uno o más sustituyentes (salvo un grupo metilo sustituido con un grupo heterocíclico de cinco miembros), un grupo heterocíclico el cual puede tener uno o más sustituyentes, un grupo amino el cual puede tener uno o más sustituyentes, un grupo acilo, y un grupo carboxi el cual puede estar esterificado; anillo Cy3 representa un anillo de cinco o seis miembros el cual puede tener uno o más sustituyentes; X representa un alquileno C1-2 el cual puede estar sustituido con hidroxi, -Y-, Y-CH2-, o -CH2-Y-; Y representa -O-, -NRb-, o -S(O)m-; Rb representa un átomo de hidrogeno o un sustituyente; m representa un entero de 0 a 2; y el anillo Cy4 representa un anillo aromático de seis miembros el cual puede tener uno o más sustituyentes (salvo un grupo sulfamoilo el cual puede tener uno o más sustituyentes); con la condicion que un compuesto representado por la formula (2) donde R1p representa alquilo o cicloalquilalquilo; R2p y R3p representan cada uno independientemente un alquilo o un cicloalquilo o representan junto con un átomo de carbono adyacente, cualquiera de los anillos de carbono de tres a seis miembros saturados o anillos heterocíclicos (donde alquilo, cicloalquilo, un anillo de carbono, o un anillo heterocíclico es insaturado o saturado); y R4p representa arilo el cual puede estar sustituido o heteroarilo el cual puede estar sustituido; un compuesto representado por la formula (3) donde Rq1 representa fenilo el cual puede tener uno o más sustituyentes; Rq2 representa hidrogeno, o un sustituyente, los otros símbolos son sinonimo con los descriptos anteriormente; un compuesto representado por la formula (4) donde Rr1 representa fenilo el cual puede tener uno o más sustituyentes; Rq2 representa hidrogeno, o un sustituyente, los otros símbolos son sinonimo con los descriptos anteriormente; 7-[4-(acetilamino)fenil]-2-(bencilsulfanil)-5-metil-N-fenil-3,7-dihidro[1,2,4]triazolo[1,5-a]pirimidin-6-carboxamida, 7-[4-(acetilamino)fenil]-2-[(4-clorobencil)sulfanil]-N-(2,4-dimetilfenil)-5-metil-3,7-dihidro[1,2,4]triazolo[1,5-a]pirimidin-6-carboxamida, 7-[4-(acetilamino)fenil]-2-(bencilsulfanil)-N-(2-metoxifenil)-5-metil-3,7-dihidro[1,2,4]triazolo[1,5-a]pirimidin-6-carboxamida, 7-[4-(acetilamino)fenil]-2-[(2,4-dimetilbencil) sulfanil]-N-(4-metoxifenil)-5-metil-3,7-dihidro[1,2,4]triazolo[1,5-a]pirimidin-6-carboxamida, 7-[4-(acetilamino)fenil]-2-(bencilsulfanil)-N-(2,4-dimetilfenil)-5-metil-3,7-dihidro[1,2,4]triazolo[1,5-a]pirimidin-6-carboxamida, N-(3-(2-((4-cloro-2-metoxi-6-metilfenil)amino)-1-metil-1H-benzoimidazol-7-il)fenil)acetamida), [4-[2-metil-1-(fenilsulfonil)-1H-pirrolo[2,3-b]piridin-4-il]fenil]carbamato de metil ter-butilo, (4-[3-[(4-metoxibencil)amino]imidazo[1,5-a]piridin-5-il]fenil)carbamato de ter-butilo, 1-[4-(dietilcarbamoil)fenil]-6-metoxi-7-fenoxi-3,4-dihidroisoquinoIin-2(1H)-carboxilato de ter-butilo, 1-[4-(dietilcarbamoil)fenil]-7-(4-fluorofenoxi)-6-metoxi-3,4-dihidroisoquinolin-2(1H)-carboxilato de ter-butilo, 1-[4-(dietilcarbamoil)fenil]-6-metoxi-7-(4-metoxi fenoxi)-3,4-dihidroisoquinolin-2(1H)-carboxilato de ter-butilo, 1-[4-(dietilcarbamoil)fenil]-6-metoxi-7-(piridin-3-iloxi)-3,4-dihidroisoquinolin-2(1H)-carboxilato de ter-butilo, 1-[4-(1-bencil-1H-pirazolo[3,4-c]piridin-4-il)fenil]-3-[3-trifluorometil)fenil]urea, 1-[4-[1-(4-metoxibencil)-1H-pirazolo[3,4-c]piridin-4-il]fenil]-3-[3-(trifluorometil)fenil]urea, 3-cloro-2-[6-[(2-cloro-4-fluorofenil)sulfanil]-2-oxo-3,4-dihidropirido[3,2-d]pirimidin-1(2H)-il]benzamida, 3,5-dicloro-4-[6-[(2,4-difluorofenil)sulfanil]-2-oxo-3,4-dihidropirido[3,2-d]pirimidin-1(2H)-il]benzamida, 3,5-dicloro-4-[6-[(2,4-difluorofenil)sulfanil]-2-oxo-3,4-dihidropirido[3,2-d]pirimidin-1(2H)-il]-N-[2-(dimetilamino)etil]benzamida, 2-cloro-N-(3-cloro-4-[2-[(4-fluorofenil)sulfanil]-6-oxo-7,8-dihidro-6H-pirimido[1,6-b]piridazin-5-il] fenil)acetamida, N-(3-cloro-4-[2-[(4-fluorofenil)sulfanil]-6-oxo-7,8-dihidro-6H-pirimido[1,6-b]piridazin-5-il]fenil)acetamida, N-(3-cloro-4-[2-[(4-fluorofenil)sulfanil]-6-oxo-7,8-dihidro-6H-pirimido[1,6-b]piridazin-5-il]fenil)-2-morfolin-4-ilacetamida, N-(4-[2-[(3,4,5-trimetoxifenil)amino]-1,3-benzoxazol-7-il]fenil)acetamida, N-(3-[2-[(3,4,5-trimetoxifenil)amino]-1,3-benzoxazol-7-il]fenil)acetamida, N-(2-amino-4-[2-[(3,4,5-trimetoxifenil)amino]-1,3-benzoxazol-7-il]fenil)formamida, 7-[4-(acetilamino)fenil]-2-[(2,4-dimetilbencil)sulfanil]-5-metil-N-fenil-3,7-dihidro[1,2,4]triazolo[1,5-a]pirimidin-6-carboxamida, 5-[(3S)-3-(dibencilamino)-3,4-dihidro-2H-cromen-5-il]-2-metoxi-N,N-dimetilpiridin-3-carboxamida, 5-[(3S)-3-(dibencilamino)-3,4-dihidro-2H-cromen-5-il]-2-metoxi-N-metilpiridin-3-carboxamida, 5-[(3S)-3-(dibencilamino)-3,4-dihidro-2H-cromen-5-il]-2-metoxi-N-metilpiridin-3-carboxamida, y N-(6-[1-[(4-metilfenil)sulfonil]-1H-pirrolo[2,3-b]piridin-4-il]piridin-2-il)acetamida, se excluyen; o una sal del mismo.
ARP090103088A 2008-08-12 2009-08-11 Compuesto amida con actividad agonista del gpr52 AR073010A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008208260 2008-08-12
JP2009129582 2009-05-28

Publications (1)

Publication Number Publication Date
AR073010A1 true AR073010A1 (es) 2010-10-06

Family

ID=41198602

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090103088A AR073010A1 (es) 2008-08-12 2009-08-11 Compuesto amida con actividad agonista del gpr52

Country Status (7)

Country Link
US (1) US20100041891A1 (es)
EP (1) EP2323978A1 (es)
JP (1) JP2011530483A (es)
AR (1) AR073010A1 (es)
TW (1) TW201010977A (es)
UY (1) UY32045A (es)
WO (1) WO2010018874A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI370820B (en) * 2005-04-27 2012-08-21 Takeda Pharmaceutical Fused heterocyclic compounds
US20110009421A1 (en) * 2008-02-27 2011-01-13 Takeda Pharmaceutical Company Limited Compound having 6-membered aromatic ring
WO2009157196A1 (ja) * 2008-06-25 2009-12-30 武田薬品工業株式会社 アミド化合物
AU2011211410B2 (en) * 2009-02-13 2013-01-31 Fovea Pharmaceuticals Sa [1,2,4] triazolo [1,5-A] pyridines as kinase inhibitors
SG173610A1 (en) * 2009-02-13 2011-09-29 Fovea Pharmaceuticals Sa [1, 2, 4] triazolo [1, 5 -a] pyridines as kinase inhibitors
AU2010254806C1 (en) 2009-06-05 2016-07-07 Cephalon, Inc. Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives
WO2011078360A1 (ja) 2009-12-24 2011-06-30 武田薬品工業株式会社 アミド化合物
EP2530078A1 (en) 2010-01-27 2012-12-05 Takeda Pharmaceutical Company Limited Thiazole derivative
WO2012020738A1 (ja) * 2010-08-09 2012-02-16 武田薬品工業株式会社 複素環化合物およびその用途
WO2012035421A2 (en) 2010-09-17 2012-03-22 Purdue Pharma L.P. Pyridine compounds and the uses thereof
GB201106750D0 (en) * 2011-04-21 2011-06-01 Glaxosmithkline Llc Novel compounds
JP6030640B2 (ja) * 2011-05-18 2016-11-24 シンジェンタ パーティシペーションズ アーゲー アリールチオアセトアミド誘導体をベースとする殺虫化合物
WO2013126283A1 (en) 2012-02-20 2013-08-29 E. I. Du Pont De Nemours And Company Fungicidal pyrazoles
EP2832725A4 (en) 2012-03-29 2015-11-25 Takeda Pharmaceutical AROMATIC RING CONNECTION
WO2014031784A1 (en) 2012-08-23 2014-02-27 Alios Biopharma, Inc. Compounds for the treatment of paramoxyvirus viral infections
US9546162B2 (en) * 2013-09-27 2017-01-17 Allergan, Inc. Compounds and methods for skin repair
PT3057964T (pt) 2013-10-14 2020-02-25 Eisai R&D Man Co Ltd Compostos de quinolina seletivamente substituídos
JP6483666B2 (ja) 2013-10-14 2019-03-13 エーザイ・アール・アンド・ディー・マネジメント株式会社 選択的に置換されたキノリン化合物
DK3180335T3 (da) 2014-08-11 2021-08-09 Angion Biomedica Corp Cytokrom-p450-inhibitorer og anvendelser deraf
CN104311479B (zh) * 2014-09-15 2016-06-15 西华大学 3,5-二碘-4-羟基吡啶的合成
WO2016109492A1 (en) 2014-12-31 2016-07-07 Angion Biomedica Corp Methods and agents for treating disease
BR112017022987A2 (pt) 2015-04-29 2018-07-24 Arena Pharm Inc 1-heteroaril-indolina-4-carboxamidas como moduladores de gpr52 úteis para o tratamento ou prevenção de distúrbios relacionados com os mesmos
CN107709311B (zh) * 2015-07-14 2020-09-25 豪夫迈·罗氏有限公司 2-苯基-6-咪唑基-吡啶-4-甲酰胺衍生物及其作为eaat3抑制剂的用途
EP3454945B1 (en) * 2016-05-12 2022-01-19 The Regents Of The University Of Michigan Ash1l inhibitors and methods of treatment therewith
WO2018237349A1 (en) * 2017-06-23 2018-12-27 University Of Washington TYPE 1 METHIONYL-ARNT SYNTHASEASE INHIBITORS AND METHODS OF USE
EP3693360B1 (en) 2017-10-06 2023-12-13 Takeda Pharmaceutical Company Limited Heterocyclic compounds
EP3908278A4 (en) 2019-01-11 2022-09-28 Naegis Pharmaceuticals Inc. LEUCOTRIENE SYNTHESIS INHIBITORS
CN111646889B (zh) * 2020-04-29 2023-01-31 兰州大学 药物活性分子gc-24和呋格雷酸的绿色合成方法
WO2024091541A1 (en) * 2022-10-26 2024-05-02 Neurocrine Biosciences, Inc. Compounds and compositions as gpr52 modulators
WO2024091538A1 (en) * 2022-10-26 2024-05-02 Neurocrine Biosciences, Inc. Compounds and compositions as gpr52 modulators

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI243164B (en) * 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
CA2550435A1 (en) * 2003-12-19 2005-07-14 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators
TWI370820B (en) * 2005-04-27 2012-08-21 Takeda Pharmaceutical Fused heterocyclic compounds
US7572808B2 (en) * 2005-06-17 2009-08-11 Bristol-Myers Squibb Company Triazolopyridine cannabinoid receptor 1 antagonists
EP1900729A1 (en) * 2006-09-15 2008-03-19 Novartis AG Benzoxazoles and oxazolopyridines being useful as Janus kinases inhibitors
GB0719803D0 (en) * 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
US20110009421A1 (en) * 2008-02-27 2011-01-13 Takeda Pharmaceutical Company Limited Compound having 6-membered aromatic ring
WO2009157196A1 (ja) * 2008-06-25 2009-12-30 武田薬品工業株式会社 アミド化合物

Also Published As

Publication number Publication date
TW201010977A (en) 2010-03-16
UY32045A (es) 2010-03-26
US20100041891A1 (en) 2010-02-18
JP2011530483A (ja) 2011-12-22
EP2323978A1 (en) 2011-05-25
WO2010018874A1 (en) 2010-02-18

Similar Documents

Publication Publication Date Title
AR073010A1 (es) Compuesto amida con actividad agonista del gpr52
CA2596013A1 (en) Benzoimidazole derivatives and pharmaceutical composition comprising the same
HRP20181014T1 (hr) Pirazoli derivati modulatori kalcijevih kanala aktiviranih oslobađanjem kalcija i metode za liječenje nesitnostaničnog karcinoma pluća
JP6732855B2 (ja) 疼痛を治療するためのアザインダゾールまたはジアザインダゾール型の誘導体
RU2586974C2 (ru) Ингибиторы катехол-о-метилтрансферазы и их применение при лечении психотических расстройств
HRP20160112T1 (hr) HETEROARIL SUPSTITUIRANI PIROLO[2,3-b]PIRIDINI I PIROLO[2,3-b]PIRIMIDINI KAO INHIBITORI JANUS KINAZE
JP5865411B2 (ja) 低酸素誘導因子−１αの安定化を増大させるための方法
PE20191147A1 (es) Modulador de regulador de conductancia de transmembrana de fibrosis quistica, composiciones farmaceuticas, metodos de tratamiento y proceso para producir el modulador
HRP20192197T2 (hr) Derivati karbazola
US10072005B2 (en) 4-azaindole derivatives
HRP20212000T1 (hr) Aminotriazolopiridini kao inhibitori kinaze
DK2925757T3 (en) Compounds and compositions for the treatment of parasitic diseases
RU2005113165A (ru) Конденсированные производные азолпиримидина
JP2018507861A5 (es)
HRP20151310T2 (hr) Spojevi piridazinona i njihova uporaba kao inhibitori daao
RU2008117329A (ru) Производные имидазопиридина как антагонисты аденозинового рецептора а2в
PE20110588A1 (es) Derivados de benzotiazol como agentes anticancerigenos
JP2005500315A5 (es)
AR114443A1 (es) Oxadiazoles fungicidas y un proceso para su preparación
JP2017535536A5 (es)
PE20141674A1 (es) Derivados de heterociclos biciclicos para el tratamiento de la hipertension arterial pulmonar
US20130317057A1 (en) Aldosterone synthase inhibitors
AR054191A1 (es) Compuestos de 3 aminopirrolidina sustituidos utiles como inhibidores de la recaptacion de monoamina
WO2016098005A1 (en) Amido thiadiazole derivatives as nadph oxidase inhibitors
JP2018530595A5 (es)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal